At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
Upcoming Events
Jefferies Healthcare Conference
In-person - London
Pharma CFO series 2024 Berenberg
Virtual
Latest News
Latest Documents
Financial Calendar
2024 Integrated Annual Report
Guidance
The figures of the guidance 2024 and 2025 as mentioned below were calculated on the same basis as the actual figures for 2023.
2024 Revenue
€ 5.5 - 5.7 billion
taking into account the launches and the continued solid contributions from the existing product portfolio.
2024 adj. EBITDA
23.0% - 24.5%
reflecting investments in launches around the globe to offer potential new solutions for people living with severe diseases and the commitment to invest into research and development to advance the late-stage and early development pipeline.
2024 Core EPS
€ 3.70 - 4.40
based on an average of 190 million shares outstanding
2025 Revenue
at least € 6 billion
2025 adj. EBITDA
Low- to mid-thirties
(at the lower end of the range)
2025 Improved ESG
rating performance
Contact UCB IR Team
investor-relations@ucb.com or a specific team member:
- Antje Witte, Head of Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com Sahar Yazdian, Investor Relations Lead
Tel: +32 2 559 9137
E-mail: Sahar.Yazdian@ucb.com
UCB IR App
